ALL |
META-ANALYSIS |
CITATIONS |
|
Benefit-Cost Summary Statistics Per Participant | ||||||
---|---|---|---|---|---|---|
Benefits to: | ||||||
Taxpayers | $17,587 | Benefits minus costs | $56,611 | |||
Participants | $32,493 | Benefit to cost ratio | $696.33 | |||
Others | $4,449 | Chance the program will produce | ||||
Indirect | $2,164 | benefits greater than the costs | 100% | |||
Total benefits | $56,693 | |||||
Net program cost | ($81) | |||||
Benefits minus cost | $56,611 | |||||
Meta-Analysis of Program Effects | ||||||||||||
Outcomes measured | Treatment age | No. of effect sizes | Treatment N | Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis | Unadjusted effect size (random effects model) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
First time ES is estimated | Second time ES is estimated | |||||||||||
ES | SE | Age | ES | SE | Age | ES | p-value | |||||
Anxiety disorder Clinical diagnosis of an anxiety disorder (e.g., general anxiety, panic, social anxiety, obsessive compulsive disorder) or symptoms measured on a validated scale. |
40 | 4 | 72 | -0.305 | 0.207 | 41 | -0.305 | 0.207 | 42 | -0.659 | 0.009 | |
Major depressive disorder Clinical diagnosis of major depression or symptoms measured on a validated scale. |
40 | 6 | 111 | -0.333 | 0.157 | 41 | -0.333 | 0.157 | 42 | -0.333 | 0.001 | |
Global functioning^ How well individuals (typically those who are developmentally disabled or seriously mentally ill) have adapted to activities of daily living. |
40 | 2 | 42 | 0.201 | 0.281 | 41 | n/a | n/a | n/a | 0.613 | 0.362 | |
Post-traumatic stress Clinical diagnosis of post-traumatic stress disorder (PTSD) or symptoms measured on a validated scale. |
40 | 11 | 224 | -0.460 | 0.134 | 41 | -0.460 | 0.134 | 42 | -0.730 | 0.001 |
Detailed Monetary Benefit Estimates Per Participant | ||||||
Affected outcome: | Resulting benefits:1 | Benefits accrue to: | ||||
---|---|---|---|---|---|---|
Taxpayers | Participants | Others2 | Indirect3 | Total |
||
Major depressive disorder | Mortality associated with depression | $2 | $4 | $0 | $49 | $54 |
Post-traumatic stress | Labor market earnings associated with PTSD | $13,274 | $31,271 | $0 | $0 | $44,545 |
Health care associated with PTSD | $4,311 | $1,219 | $4,449 | $2,156 | $12,134 | |
Program cost | Adjustment for deadweight cost of program | $0 | $0 | $0 | ($41) | ($41) |
Totals | $17,587 | $32,493 | $4,449 | $2,164 | $56,693 | |
Detailed Annual Cost Estimates Per Participant | ||||
Annual cost | Year dollars | Summary | ||
---|---|---|---|---|
Program costs | $974 | 2014 | Present value of net program costs (in 2022 dollars) | ($81) |
Comparison costs | $830 | 2008 | Cost range (+ or -) | 10% |
Benefits Minus Costs |
Benefits by Perspective |
Taxpayer Benefits by Source of Value |
Benefits Minus Costs Over Time (Cumulative Discounted Dollars) |
The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment. |
Boudewyns, P.A., Stwertka, S.A., Hyer, L.A., Albrecht, J.W., & Sperr, E.V. (1993). Eye movement desensitization for PTSD of combat: A treatment outcome pilot study. The Behavior Therapist, 16(2), 29-33.
Carlson, J.G., Chemtob, C.M., Rusnak, K., Hedlund, N.L., & Muraoka, M.Y. (1998). Eye Movement Desensitization and Reprocessing (EDMR) treatment for combat-related posttraumatic stress disorder. Journal of Traumatic Stress, 11(1), 3-24.
Högberg, G., Pagani, M., Sundin, O., Soares, J., Åberg-Wistedt, A., Tärnell, B., & Hällström, T. (2007). On treatment with eye movement desensitization and reprocessing of chronic post-traumatic stress disorder in public transportation workers—A randomized controlled trial. Nordic Journal of Psychiatry, 61(1), 54-61.
Jensen, J.A. (1994). An investigation of eye movement desensitization and reprocessing (EMD/R) as a treatment for posttraumatic stress disorder (PTSD) symptoms of Vietnam combat veterans. Behavior Therapy, 25(2), 311-325.
Johnson, D.R., & Lubin, H. (2006). The counting method: Applying the rule of parsimony to the treatment of posttraumatic stress disorder. Traumatology, 12(1), 83-99.
Marcus, S.V., Marquis, P., & Sakai, C. (1997). Controlled study of treatment of PTSD using EMDR in an HMO setting. Psychotherapy: Theory, Research, Practice, Training, 34(3), 307-315.
Rothbaum, B.O., Austin, M.C., & Marsteller, F. (2005). Prolonged exposure versus eye movement desensitization and reprocessing (EMDR) for PTSD rape victims. Journal of Traumatic Stress: Publ. for the Society for Traumatic Stress Studies, 18(6), 607-616.
Rothbaum, B.O. (1997). Acontrolled study of eye movement desensitization and reprocessing in the treatment of posttraumatic stress disordered sexual assault victims. Bulletin of the Menninger Clinic, 61(3), 317-334.
Taylor, S., Thordarson, D.S., Maxfield, L., Fedoroff, I.C., Lovell, K., & Ogrodniczuk, J. (2003). Comparative efficacy, speed, and adverse effects of three PTSD treatments: exposure therapy, EMDR, and relaxation training. Journal of Consulting and Clinical Psychology, 71(2), 330-338.
van den Berg, D.P.G., de Bont, P.A.J.M, Berber M.v.d.V, de Roos, C., de Jongh, A., Van Minnen, A., & van der Gaag, M. (2015). Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial. Jama Psychiatry, 72(3), 259-67.
van der Kolk, B.A., Spinazzola, J., Blaustein, M.E., Hopper, J.W., Hopper, E.K., Korn, D.L., & Simpson, W.B. (2007). A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. The Journal of Clinical Psychiatry, 68(1), 37-46.